Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials
By
- AMS
posted
Jan 04, 2020 03:00 AM
0
Recommend
Volume 32, Issue 7
, November 2021, Page 709-715
.
0 comments
0 views
Permalink
Related Content
Four-weeks daily intake of oral collagen hydrolysate results in improved skin elasticity, especially in sun-exposed areas: a randomized, double-blind, placebo-controlled trial
- AMS
Added Mar 10, 2020
Blog Entry
Concomitant atopic dermatitis and psoriasis – a retrospective review
- AMS
Added Dec 18, 2019
Blog Entry
Efficacy of fractional carbon dioxide laser therapy for burn scars: a meta-analysis
- AMS
Added Dec 23, 2019
Blog Entry
A split-face randomized controlled trial of treatment with broadband light for enlarged facial pores
- AMS
Added Dec 05, 2019
Blog Entry
The randomized trials of 10% urea cream and 0.025% tretinoin cream in the treatment of acanthosis nigricans
- AMS
Added Jan 04, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic